InvestorsHub Logo
icon url

Larrybirdlegend

05/31/19 7:33 PM

#194547 RE: SonamKapoor #194546

Sonam, good to see you back

Do you think they will run into any supply issues going forward, particularly once demand exceeds billion or multi billions per year in revenue?

Also w regards to BASF what’s your takeaway w then re-emerging in the future? Im of the understanding amrn and basf parted ways on very good terms and I suspect if supply questions arise basf seems logical match, particularly since they’re business model usually identifies ways to produce better output w better margins. So any thoughts you can share on basf also?
icon url

KevGee59

05/31/19 7:36 PM

#194548 RE: SonamKapoor #194546

Sonam....
What do you make of this plant being 'permanently mothballed' by BASF?

Also...the article (new one) said something about losing a patent lawsuit in the US was basis for at least part of the decision.

TIA

KG ;)

Edit***Mis-read the article. It seems that all happened in 2014. The lawsuit...et al
icon url

IgnoranceIsBliss

05/31/19 7:40 PM

#194550 RE: SonamKapoor #194546

Yay! SK is back!

I think you did estimates for us at one point about how much Vascepa could reasonably be produced annually... yes?
icon url

Dancing in the dark

05/31/19 7:49 PM

#194551 RE: SonamKapoor #194546

Kalundborg, Sweden plant could go a long way in the vascepa supply chain

CONSTRUCTION STARTED
October 2007

COMPLETION
Structurally complete in January 2009, producing by May 2009, validation completed and first commercial batches by spring 2010

https://www.pharmaceutical-technology.com/projects/pronova-biopharma/